Insights Into Breast Cancer
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease
Southwest – January 14, 2023
Faculty Chair
Joyce O'Shaughnessy, MD
Texas Oncology, Dallas, TX, USA
More Information
- Las Vegas, NV
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Baltimore, MD
- Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of breast cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
